issu
isar
news
kindli
put
togeth
guest
editor
graciela
andrei
sure
appreci
effort
put
spotlight
number
interest
articl
issu
also
find
short
biosketch
candid
run
either
posit
isar
board
director
secretari
grate
candid
utmost
import
success
futur
isaricar
dedic
compet
peopl
will
take
leadership
societi
pleas
kindli
bring
vote
issu
also
find
text
mike
bray
present
speaker
alreadi
accept
talk
icar
lineup
excel
speaker
cover
rang
interest
topic
attract
larg
crowd
meet
pleas
help
us
spread
inform
believ
may
interest
attend
icar
find
biographi
speaker
also
websit
wwwisaricarcom
would
also
like
kindli
remind
everyon
invit
nd
icar
baltimor
maryland
usa
subscrib
via
websit
isar
mail
pleas
also
follow
linkedin
facebook
page
well
isar
twitter
account
access
via
websit
elect
held
electron
open
soon
email
sent
isar
member
explain
vote
strongli
encourag
member
societi
vote
wish
best
year
candid
sinc
maaik
associ
director
alabama
drug
discoveri
allianc
collabor
uab
southern
research
goal
find
new
smallmolecul
drug
unmet
medic
need
varieti
therapeut
area
also
assist
physicianinvestig
ind
applic
process
provid
qualiti
assur
uab
vector
product
facil
manufactur
novel
drug
phase
clinic
trial
also
administr
director
antivir
drug
discoveri
develop
center
multiinstitut
consortium
fund
grant
niaid
maaik
join
isar
invit
join
women
scienc
committe
respons
organ
career
develop
panel
lui
attend
first
icar
baltimor
member
public
committe
societi
sinc
poster
award
committe
sinc
ambassador
program
south
america
canada
sinc
becam
cochair
public
committe
togeth
anthoni
vere
hodg
earlier
year
regularli
guest
edit
isar
news
issu
lui
molecular
virologist
interest
use
chemic
biolog
learn
interact
virus
infect
cell
interact
determin
outcom
infect
particularli
interest
identifi
common
among
unrel
virus
lui
group
work
number
establish
human
pathogen
includ
herp
simplex
viru
hepat
c
viru
hcv
influenza
viru
iav
emerg
virus
zika
viru
research
team
lui
identifi
design
small
molecul
inhibit
infect
replic
varieti
unrel
virus
use
compound
probe
identifi
common
among
affect
virus
research
answer
fundament
question
molecular
virolog
identifi
biolog
activ
small
molecul
scaffold
may
develop
antivir
use
approach
group
identifi
new
famili
compound
antivir
activ
multipl
unrel
virus
broadspectrum
antivir
activ
well
compound
act
exclus
singl
virus
interest
compound
novel
target
mechan
action
first
lipid
target
antivir
molecul
rafi
work
result
public
patent
issu
eeuu
european
union
canada
china
japan
lui
member
editori
board
sever
journal
antivir
area
includ
offici
public
societi
antivir
research
well
antimicrobi
chemistri
chemotherapi
acc
journal
virolog
offici
journal
american
societi
microbiolog
asm
also
section
editor
plo
one
editor
virolog
journal
contribut
review
manuscript
number
public
includ
plo
pathogen
mbio
elif
among
mani
other
review
grant
nih
canadian
institut
health
research
sever
argentinean
uk
polish
belgian
hong
kong
agenc
among
other
fever
virus
program
investig
molecular
mechan
pathogenesi
develop
anim
model
diseas
conduct
vivo
screen
therapeut
vaccin
candid
highcontain
highconsequ
viral
hemorrhag
fever
investig
program
emerg
infecti
diseas
duken
univers
singapor
medic
school
subhash
vasudevan
born
singapor
obtain
bsc
hon
chemistri
la
trobe
univers
australia
phd
biochemistri
australian
nation
univers
anu
follow
postdoctor
train
maxplanck
institut
biophys
germani
research
school
chemistri
anu
establish
first
independ
research
laboratori
jame
cook
univers
australia
appoint
lectur
biochemistri
molecular
biolog
rose
rank
becom
reader
assoc
professor
period
start
work
dengu
viru
focus
mainli
protein
move
singapor
inaugur
unit
head
dengu
research
unit
newli
establish
novarti
institut
tropic
diseas
led
intens
effort
find
directli
act
antivir
dengu
viru
serotyp
recruit
signatur
research
program
emerg
infecti
diseas
duken
univers
singapor
medic
school
current
pursu
research
interest
dengu
zika
pathogenesi
antivir
drug
discoveri
develop
appoint
editor
antivir
research
elsevi
member
editori
board
journal
virolog
recent
subhash
start
becom
involv
isar
tri
increas
membership
asia
also
hope
attract
help
organ
togeth
griffith
universitysinstitut
glycom
icar
gold
coast
australia
intern
societi
antivir
research
isar
host
nd
intern
confer
antivir
research
icar
hyatt
regenc
baltimor
inner
harbor
usa
confer
begin
sunday
may
conclud
wednesday
may
abstract
submiss
open
sunday
afternoon
one
two
keynot
lectur
given
dian
griffin
professor
infecti
diseas
neurolog
john
hopkin
bloomberg
school
public
health
vicepresid
us
nation
academi
scienc
present
research
find
pathogenesi
measl
persist
infect
central
nervou
system
second
keynot
speaker
invit
yet
confirm
jeff
taubenberg
session
influenza
fred
hayden
professor
emeritu
univers
virginia
review
approv
antivir
promis
new
drug
develop
jefferi
taubenberg
deputi
chief
laboratori
infecti
diseas
niaidnih
discuss
legaci
pandem
current
effort
develop
univers
flu
vaccin
florian
krammer
associ
professor
icahn
school
medicin
mount
sinai
new
york
citi
talk
studi
antibodi
respons
antigen
site
influenza
ha
stalk
target
viral
surfac
glycoprotein
addit
invit
pend
area
retrovir
diseas
bob
gallo
director
institut
human
virolog
univers
maryland
medic
school
review
global
burden
infect
need
research
public
health
respons
marina
caskey
associ
professor
clinic
research
rockefel
univers
discuss
develop
evalu
broadli
neutral
antibodi
addit
invit
pend
permit
coverag
wide
rang
topic
organ
two
session
invit
lectur
new
antivir
research
tim
block
director
hepat
b
institut
doylestown
pa
review
current
effort
develop
effect
potenti
cur
therapi
chronic
hepat
b
vicki
olson
chief
poxviru
rabi
branch
us
cdc
atlanta
describ
ongo
research
variola
viru
current
statu
countermeasur
possibl
reintroduct
smallpox
marc
collett
founder
director
virodefens
devot
develop
antivir
polioviru
describ
need
treat
immunodefici
individu
chronic
shed
vaccinederiv
poliovirus
futur
global
erad
endgam
subhash
vasudevan
duken
univers
singapor
provid
updat
develop
antivir
flaviviru
infect
addit
speaker
pend
session
emerg
viral
diseas
amad
sall
scientif
director
pasteur
institut
dakar
seneg
review
emerg
virus
africa
ebola
emili
gurley
associ
scientist
john
hopkin
school
public
health
describ
experi
investig
outbreak
nipah
viru
infect
southeast
asia
develop
behavior
pharmaceut
intervent
prevent
spread
infect
scott
weaver
chu
famili
scholarship
initi
chu
famili
foundat
tcff
isar
support
profession
develop
earli
career
level
women
provid
fund
attend
special
workshop
visitwork
anoth
laboratori
obtain
new
skill
take
cours
acquir
special
train
three
award
given
biannual
advanc
career
earli
career
level
women
potenti
signific
contribut
field
basic
appli
clinic
aspect
antivir
research
antivir
drug
develop
award
consist
stipend
isar
membership
commemor
plaqu
stipend
must
use
within
year
award
winner
must
present
research
next
intern
confer
antivir
research
icar
result
award
use
propos
extern
train
attend
icar
howev
total
cost
exce
limit
applic
still
elig
appli
icar
travel
award
fund
fund
meant
howev
attend
icar
elig
appli
tcff
award
earli
career
level
woman
scientist
must
current
either
graduat
student
ii
hold
doctor
degre
four
year
cumul
postdoctor
experi
applic
must
current
graduat
postdoctor
research
gener
field
antivir
research
includ
virolog
chemistri
molecular
biolog
anoth
virallyrel
focu
criteria
select
includ
limit
level
interest
antivir
research
abil
independ
scientif
work
potenti
high
level
scientif
endeavor
antivir
research
well
extent
scientif
accomplish
scientif
leadershipmentor
skill
graduat
student
postdoctor
candid
must
member
isar
letter
support
must
provid
nomin
may
candid
research
project
director
depart
chair
center
director
click
wwwisaricarcom
inform
becom
isar
member
grant
applic
must
submit
electron
decemb
submit
nomin
materi
becom
properti
select
committe
return
winner
select
tcff
candid
wish
use
award
money
visit
anoth
scientist
laboratori
must
also
submit
letter
head
laboratori
indic
propos
visit
permiss
candid
wish
use
award
money
attend
special
cours
workshop
cours
must
provid
detail
descript
conferencecours
includ
date
locat
pertin
detail
includ
link
onlin
inform
candid
may
appli
one
time
women
previous
award
elig
second
award
addit
candid
tcff
scholarship
intern
societi
nucleosid
nucleotid
nucleic
acid
inelig
appli
gener
career
develop
activ
one
applic
advisor
alreadi
fund
complet
train
cours
etc
recipi
must
provid
brief
report
work
support
award
isar
report
sent
chu
famili
foundat
question
pleas
contact
tcff
chair
professor
katherin
seleyradtk
kseley
umbcedu
word
chu
famili
foundat
scholarship
subject
titl
year
isar
pleas
announc
avail
singl
type
travel
grant
differ
level
award
base
region
origin
applic
award
aim
stimul
particip
student
postdoc
young
research
provid
opportun
recogn
scientif
contribut
antivir
research
isar
grant
award
base
qualiti
submit
abstract
need
support
travel
meet
least
three
independ
review
evalu
scientif
qualiti
submit
abstract
abstract
rank
accord
score
provid
review
stipend
vari
depend
region
origin
present
author
europ
asia
australia
south
america
north
america
low
middl
incom
countri
defin
world
bank
complimentari
registr
icar
meet
registr
meet
mandatori
recipi
travel
award
registr
fee
waiv
come
low
middl
incom
countri
pleas
check
isar
websit
select
criteria
elig
requir
appli
travel
award
pleas
submit
abstract
submiss
system
reach
final
page
submiss
form
prompt
attach
cv
includ
public
record
nomin
letter
icar
meet
head
depart
andor
princip
investig
pleas
keep
mind
abstract
submit
second
submiss
period
elig
travel
award
applic
deadlin
travel
grant
januari
applic
notifi
email
februari
award
statu
travel
award
distribut
meet
receipt
sign
one
hundr
year
ago
first
world
war
end
world
face
anoth
catastroph
spanish
flu
pandem
influenza
pandem
among
deadli
outbreak
record
human
histori
one
third
entir
global
popul
probabl
caught
spanish
flu
million
corner
world
kill
one
adjust
popul
growth
extrapol
present
popul
equival
million
million
today
spanish
flu
name
spain
one
neutral
countri
provid
report
outbreak
decim
mainli
adult
age
contrast
flu
season
death
occur
mainli
elderli
children
five
influenza
pandem
three
distinct
wave
first
wave
exceedingli
infecti
clinic
mild
second
one
autumn
also
highli
infecti
much
higher
mortal
third
wave
winter
associ
fewer
case
less
mortal
second
wave
three
wave
infect
often
assum
share
viru
howev
recent
evid
first
second
wave
infect
probabl
caus
antigen
distinct
influenza
virus
one
viru
suddenli
increas
pathogen
two
wave
centuri
ago
caus
spanish
flu
unknown
vaccin
develop
earli
stage
vaccin
protect
influenza
viru
infect
antivir
drug
treat
diseas
antibiot
treat
secondari
bacteri
infect
pneumonia
main
respons
spanish
flu
consist
nonpharmaceut
intervent
school
close
restrict
larg
gather
isol
quarantin
first
decad
th
centuri
healthcar
notion
mani
peopl
access
doctor
either
work
fund
chariti
religi
institut
spanish
flu
regard
inflect
point
histori
epidem
respons
global
health
follow
mass
death
caus
spanish
flu
health
author
realiz
individu
could
blame
catch
infecti
diseas
mani
govern
embrac
concept
social
medicin
recogn
well
need
coordin
public
health
intern
level
sinc
contagi
diseas
border
sinc
flu
pandem
tremend
advanc
made
character
viru
caus
pandem
treat
prevent
influenza
viru
infect
nevertheless
mani
question
remain
unansw
flu
virus
continu
pose
seriou
public
health
threat
therefor
remain
alert
use
knowledg
gain
influenza
pandem
target
research
effort
prepared
plan
eventu
new
deadli
pandem
influenza
focu
prevent
contain
treatment
sinc
spanish
flu
influenza
pandem
though
less
sever
occur
similar
big
earthquak
hit
california
one
day
influenza
viru
expert
believ
new
influenza
pandem
inevit
appear
one
point
futur
big
question
happen
centenari
pandem
pertin
wonder
whether
world
would
prepar
event
unfortun
fulli
prepar
face
new
influenza
pandem
first
know
influenza
viru
caus
next
pandem
due
increas
mobil
viru
rapidli
spread
today
way
develop
promptli
effect
vaccin
pandem
viru
differ
qualiti
health
system
imped
prompt
global
respons
major
gap
exist
regard
surveil
data
emerg
influenza
viru
year
th
anniversari
spanish
flu
pandem
also
centuri
sinc
women
got
right
vote
centuri
end
first
word
war
year
univers
declar
human
right
year
may
protest
year
martin
luther
king
die
year
sinc
state
israel
born
event
unquestion
mark
human
histori
spanish
flu
one
devast
event
human
histori
also
central
histor
event
virolog
contribut
reflect
evolut
virolog
pandem
central
point
session
focus
impact
big
discoveri
virolog
took
place
decennia
interv
spanish
flu
year
rememb
th
anniversari
flu
pandem
also
year
discoveri
leporipoxviru
myxoma
viru
year
descript
reedmuench
method
year
discoveri
coxsacki
virus
year
freedom
smallpox
year
human
herpesviru
link
exanthema
subitum
year
sinc
discoveri
rna
interfer
event
profoundli
influenc
virolog
research
aim
highlight
impact
past
present
futur
research
univers
alberta
edmonton
alberta
canada
devan
ualbertaca
studi
myxoma
viru
myxv
offer
critic
import
insight
biolog
natur
histori
viru
infect
document
follow
tri
summar
centuri
myxoma
research
highlight
discoveri
myxv
poxviru
one
extens
famili
larg
dna
virus
infect
organ
rang
insect
whale
first
discov
coloni
european
rabbit
oryctolagu
cuniculu
montevideo
contract
highli
lethal
diseas
call
myxomatosi
discover
professor
g
sanarelli
infect
anim
exhibit
multipl
skin
lesion
character
tumourlik
growth
die
within
day
infect
modern
investig
subsequ
note
high
viremia
death
often
caus
secondari
infect
aris
profound
immun
suppress
infect
anim
high
infect
also
indic
earli
studi
show
singl
particl
seem
correspond
infecti
unit
sourc
sporad
south
america
infect
long
remain
mysteri
myxomatosi
found
endem
nativ
popul
wild
rabbit
sylvilagu
brasiliensi
speci
control
myxv
local
infect
within
singl
infect
site
although
tumour
still
aid
viru
propag
medium
bite
insect
vector
anoth
strain
myxv
subsequ
discov
infect
popul
sylvilagu
bachmani
california
third
viru
also
discov
produc
benign
fibromalik
infect
floridanu
rabbit
across
northeastern
usa
subsequ
shown
provid
immunolog
crossprotect
myxv
myxoma
shope
fibroma
viru
assign
taxonom
genu
leporipoxviru
high
mortal
rate
associ
myxv
infect
escap
notic
research
other
concern
environment
damag
caus
cuniculu
absenc
natur
predat
histori
impact
anim
especi
well
document
australia
interest
reader
find
authorit
descript
book
myxomatosi
briefli
shipment
rabbit
releas
estat
near
southeast
tip
australia
within
space
decad
stun
illustr
exponenti
popul
growth
succeed
cross
contin
rate
estim
milesyear
idea
anim
might
control
myxv
first
float
would
take
seri
onandoff
trial
govern
review
diseas
final
gain
perman
foothold
zoonot
infect
australian
rabbit
earli
trial
serv
import
role
demonstr
myxv
limit
host
rang
also
critic
import
ecolog
factor
rainfal
insect
vector
spread
diseas
around
time
diseas
introduc
europ
sinc
establish
perman
presenc
well
coupl
decad
follow
myxv
introduct
australia
research
could
watch
grand
scale
experi
sinc
come
play
import
role
understand
diseas
dynam
interest
reader
find
detail
descript
fenner
ratcliff
viru
releas
spread
rapidli
cross
contin
westward
three
year
one
import
observ
highli
pathogen
myxv
strain
strong
tendenc
die
replac
attenu
strain
exampl
standard
australian
laboratori
strain
produc
casemort
rate
within
year
field
reduc
circul
myxv
strain
time
also
observ
wild
popul
rabbit
rapidli
evolv
resist
strain
myxv
use
infect
nonimmun
rabbit
captur
seri
repeat
epizoot
strain
produc
mortal
among
rabbit
captur
begin
project
year
seven
reduc
european
investig
observ
similar
trend
myxv
research
continu
line
investig
meanwhil
smallpox
declar
erad
focu
poxviru
field
shift
heavili
toward
studi
vaccinia
viru
standard
model
poxviru
infect
discoveri
virus
caus
cancer
creat
interest
tumourlik
growth
character
leporipoxviru
infect
subsequ
research
shown
transform
virus
phenotyp
depend
upon
combin
immun
suppress
virusencod
cell
growth
factor
earli
molecular
biolog
began
appli
tool
myxv
research
much
pioneer
laboratori
grant
mcfadden
canada
david
strayer
also
contribut
earli
insight
immunolog
properti
virus
studi
hybrid
myxv
shope
fibroma
viru
call
malign
rabbit
fibroma
viru
myxv
offer
invit
model
explor
complex
array
gene
collect
promot
diseas
advent
poxviru
gene
knockout
technolog
becam
possibl
select
delet
myxv
gene
test
effect
diseas
rabbit
use
approach
combin
gene
sequenc
rapidli
evolv
comput
tool
great
number
myxv
pathogen
subsequ
identifi
earli
exampl
virusencod
homolog
cellular
serpin
tnf
receptor
common
theme
began
emerg
homolog
host
gene
repurpos
nefari
end
discoveri
myxv
downregul
mhc
class
molecul
surfac
infect
cell
also
provid
key
insight
immunosuppress
character
myxv
infect
mani
excel
review
summar
extens
still
grow
literatur
subject
eg
first
complet
genom
sequenc
report
vaccinia
variola
virus
valu
approach
rapidli
appreci
research
studi
poxvirus
complet
genom
sequenc
myxv
shope
fibroma
viru
report
backtoback
paper
work
show
two
virus
share
common
ancestor
long
evolv
isol
environ
shope
fibroma
viru
attenu
gene
loss
unanticip
discoveri
virus
encod
photolyas
dna
repair
protein
provid
protect
damag
effect
ultraviolet
light
first
decad
st
centuri
continu
studi
explor
myxv
pathogenesi
research
like
peter
kerr
toni
robinson
continu
explor
biolog
australia
still
evolv
myvx
rabbit
strain
work
without
controversi
effort
develop
myxv
less
virul
vaccin
vector
led
discoveri
incorpor
one
propos
genet
modif
ectromelia
viru
could
break
preexist
immun
public
sensit
releas
genet
modifi
organ
meant
plan
yet
come
fruition
period
collect
understand
also
began
emerg
concern
oper
cellular
innat
immun
signal
network
among
mani
discoveri
shown
myxv
ca
nt
block
interferontrigg
activ
resist
speci
provid
import
insight
factor
determin
myxv
host
rang
signal
network
essenti
burglar
alarm
virus
trigger
other
evolv
strategi
disarm
cancer
research
big
driver
behind
studi
cellsignal
network
cancer
cell
accumul
mutat
disabl
pathway
play
key
role
help
tumour
evad
immun
surveil
exampl
mutat
alter
express
apoptot
regul
inhibit
apoptosi
thu
block
tcell
induc
kill
sinc
mani
system
provid
defens
virus
import
consequ
virus
would
infect
nontransform
cell
sometim
infect
cancer
cell
principl
behind
oncolyt
viru
technolog
peter
forsyth
laboratori
first
illustr
oncolyt
potenti
myxv
vivo
demonstr
capac
erad
glioblastoma
tumour
xenograft
mous
model
recent
myxvbas
virotherapi
shown
particular
promis
treat
blood
malign
use
conjunct
allogen
hematopoiet
cell
transplant
mous
model
procedur
hazard
risk
graft
versu
host
diseas
myxv
treatment
control
dormant
virus
gain
opportun
replic
disabl
activ
tcell
activ
tcell
deliv
viru
payload
target
cell
thu
also
kill
residu
myeloma
cell
recent
review
summar
excit
still
grow
oncolyt
viru
literatur
eg
commentari
began
summar
histori
australia
grand
biolog
experi
seem
appropri
conclud
note
last
year
peter
kerr
colleagu
use
next
gener
sequenc
technolog
determin
sequenc
australian
british
myxv
strain
studi
provid
detail
insight
evolutionari
trajectori
follow
differ
wild
strain
includ
propens
accumul
gene
duplic
delet
rather
surprisingli
proven
difficult
link
specif
mutat
chang
virul
suggest
singlegen
knockout
studi
laboratori
may
reflect
diseas
wild
interestingli
diseas
phenotyp
compar
modern
archiv
strain
modern
strain
seem
revers
trend
toward
attenu
seen
virus
virul
caus
differ
diseas
laboratori
rabbit
call
immun
acut
collaps
resembl
way
septic
shock
syndrom
similar
diseas
call
amyxomat
myxomatosi
previous
describ
europ
like
australian
strain
form
cutan
lesion
seen
classic
infect
laboratori
anim
kerr
et
al
propos
attract
hypothesi
phenotyp
reflect
way
myxv
adapt
maintain
transmiss
face
enhanc
host
resist
infect
howev
although
virus
sequenc
obviou
genet
signatur
would
explain
alter
diseas
phenotyp
clearli
still
lot
learn
myxoma
viru
alfr
crosbi
wrote
pioneer
book
spanish
influenza
conclud
physician
particip
greatest
failur
medic
scienc
th
centuri
absolut
number
dead
measur
time
view
outbreak
kill
mani
million
caus
seriou
ill
anoth
million
centuri
later
scientif
respons
look
less
bleak
remark
individu
scientist
uk
usa
produc
batch
bacteri
vaccin
prevent
seriou
pneumonia
death
also
local
outbreak
particularli
usa
introduc
layer
public
health
approach
social
distanc
cotton
mask
hygien
school
closur
citi
benefit
citizen
local
doctor
use
passiv
antibodi
taken
patient
recov
other
desper
set
tent
patient
treat
steam
oxygen
eucalyptu
rather
failur
result
poor
medic
infrastructur
leadership
combat
epidem
mani
countri
world
includ
england
epidem
infect
british
armi
first
two
year
great
war
howev
continu
small
number
case
typhoid
paratyphoid
respiratori
infect
cerebrospin
fever
even
smallpox
suddenli
decemb
ensu
month
influenza
like
ill
call
purul
bronchiti
pathologist
etapl
isol
pneumococcu
streptococcu
mani
victim
diseas
began
formul
complex
vaccin
grew
streptococcu
pneumococcu
controversi
binfluenza
pfeiffer
bacillu
bacterium
agar
suspend
million
organ
per
millimetr
heattreat
c
minut
ad
preserv
bottl
new
vaccin
small
vial
readi
inject
soldier
quit
remark
small
group
research
could
take
initi
cours
technolog
bacteri
vaccin
product
small
scale
say
dose
technic
quit
simpl
take
elementari
precaut
prepar
clean
room
free
bacteria
vaccin
could
made
even
field
laboratori
wooden
shed
use
dr
hammond
etapl
retrospect
know
perhap
half
victim
pandem
influenza
die
deepseat
super
infect
respiratori
bacteria
like
streptococcu
staphylococcu
today
polyval
pneumococcu
vaccin
stockpil
use
pandem
event
end
winter
year
march
coincid
end
epidem
purul
bronchiti
vaccin
project
unexpectedli
put
hold
author
must
extens
discuss
among
superior
ramc
royal
armi
medic
corp
possibl
small
epidem
involv
hundr
men
spread
wide
amongst
ten
thousand
soldier
camp
etapl
later
outsid
influenza
presum
case
civilian
countrysid
around
etapl
time
unfortun
medic
record
destroy
passag
time
world
would
react
differ
arm
new
knowledg
hindsight
virologist
pathologist
today
would
fit
togeth
scenario
emerg
influenza
pandem
use
china
current
model
today
world
health
organis
full
alert
everi
nation
world
ask
plan
pandem
bird
influenza
earlier
prepandem
outbreak
etapl
china
today
fewer
thousand
death
popul
two
billion
spread
commun
appreci
remark
brave
gain
function
anim
experi
viru
would
need
mutat
ha
gene
enabl
spread
postul
similar
scenario
could
happen
western
front
also
mutat
viru
perhap
usa
armi
camp
complet
evolut
darwinian
viru
spread
back
europ
rest
world
receiv
one
dose
vaccin
risk
death
sever
complic
case
two
group
per
cent
receiv
full
vaccin
per
cent
cours
vaccin
would
prevent
infect
viru
could
reduc
secondari
bacteri
infect
still
immort
continu
appli
research
eas
use
current
short
review
focus
develop
use
reedmuench
method
pure
virologist
view
viru
infect
measur
either
quantal
quantit
assay
quantal
assay
base
noney
principl
exampl
live
dead
infect
anim
embryon
chicken
egg
presenc
absenc
cytopath
effect
cpe
cell
cultur
etc
infecti
unit
measur
term
median
dose
lethal
dose
anim
embryo
infecti
dose
embryon
chicken
egg
tissu
cultur
infecti
dose
cell
cultur
etc
case
quantit
assay
infect
measur
accur
absolut
unit
plaqu
form
unit
pfu
focu
form
unit
ffu
pock
unit
etc
plaqu
assay
consid
gold
standard
viru
titrat
howev
virus
produc
cpe
plaqu
cell
cultur
virus
need
measur
term
origin
trevan
introduc
term
median
lethal
dose
assay
particular
dilut
viru
concentr
anim
die
wherea
anim
remain
live
mani
time
may
encount
question
student
ask
viru
need
measur
term
median
dose
valu
detail
statist
explan
select
median
rather
mean
mode
found
classic
literatur
brief
viru
titer
measur
unit
infect
error
rate
valu
compar
sever
formula
avail
estim
median
lethal
dose
howev
two
longlast
method
reedmuench
spearmankarb
still
use
research
lowel
jacob
read
januari
median
dose
calcul
reedmuench
method
still
prefer
mani
research
rel
eas
use
reduc
dose
rang
possibl
method
requir
valu
measur
median
dose
initi
method
use
endpoint
estim
yellow
fever
laboratori
rockefel
foundat
later
reed
muench
duo
simplifi
method
reedmuench
origin
articl
explain
method
calcul
protect
serum
appli
viru
titrat
formula
need
modifi
accordingli
mani
author
quot
formula
differ
way
especi
use
symbol
dilut
dilut
factor
follow
formula
taken
simpl
clear
formula
noteworthi
clarifi
follow
point
proport
proportion
distanc
also
known
interpol
valu
differ
logarithm
minu
symbol
applic
log
dilut
dilut
factor
log
id
endpoint
dilut
ie
minimum
dilut
experiment
unit
infect
exampl
death
anim
embryo
etc
case
minim
dose
requir
infect
well
well
etc
cell
popul
thu
well
show
cpe
well
show
indic
cpe
equal
score
plu
cpe
minu
viru
titer
reciproc
end
dilut
although
method
popular
among
research
similar
method
avail
sever
research
compar
differ
median
calcul
method
observ
recent
spearmankarb
method
superior
biolog
assay
method
reed
muench
also
merit
demerit
applic
howev
method
serv
sever
virolog
breakthrough
still
recommend
intern
agenc
vaccin
relat
work
coxsackievirus
classifi
group
b
depend
upon
type
paralysi
induc
suckl
mice
coxsackievirus
group
cva
produc
myositisbas
flaccid
hind
limb
paralysi
group
b
cvb
produc
spastic
paralysi
gener
infect
newborn
mice
member
cvb
famili
observ
caus
damag
heart
brain
pancrea
fat
tissu
newborn
mice
cv
fall
within
picornavirida
famili
enteroviru
genu
separ
accord
speci
cv
split
b
c
speci
enteroviru
shown
tabl
along
associ
ill
attribut
cv
infect
cv
infect
respons
wide
rang
diseas
rang
handfootandmouth
diseas
hfmd
pericard
infant
cv
primari
agent
hfmd
well
potenti
caus
acut
meningoenceph
flaccid
paralysi
cv
infect
report
track
nation
enteroviru
surveil
system
ness
unit
state
well
polio
erad
initi
world
health
organ
addit
diseas
cv
infect
known
caus
cv
infect
implic
onset
type
diabet
link
cv
definit
shown
infect
thymu
mice
well
fetal
thymu
organ
cultur
cv
may
caus
rapid
complet
destruct
pancreat
beta
cell
lead
fulmin
research
need
conclus
evid
cv
infect
potenti
factor
develop
genom
coxsackieviru
similar
enterovirus
singlestrand
positivesens
rna
genom
encod
singl
polyprotein
enzymat
cleav
viral
proteas
total
protein
separ
four
structur
protein
seven
nonstructur
protein
cv
life
cycl
follow
similar
step
enterovirus
viru
first
attach
cell
surfac
receptor
endocytosi
uncoat
translat
proteolyt
process
genom
replic
assembl
virion
matur
releas
viru
releas
either
lytic
nonlyt
mechan
sever
receptor
implic
entri
cv
host
cell
mani
experi
requir
demonstr
role
receptor
coxsackieviru
infect
brief
overview
present
intracellular
adhes
molecul
implic
infect
normal
function
process
extravas
neutrophil
surround
tissu
v
vitronectin
receptor
shown
allow
infect
green
monkey
kidney
cell
integrin
express
platelet
bone
reabsorb
cell
osteoclast
mediat
cell
adhes
extracellular
matrix
decayacceler
factor
daf
also
known
shown
import
daf
widespread
regulatori
membran
protein
respons
dissoci
complement
pathway
studi
shown
insert
coxsackieviru
adenoviru
receptor
car
render
nonpermiss
cell
suscept
infect
cvb
car
normal
function
cell
adhes
molecul
may
role
scaffold
heparan
sulfat
also
shown
aid
infect
cell
lack
car
daf
exact
role
receptor
focu
ongo
research
receptor
specif
cv
may
influenc
tissu
tropism
pathogenesi
compound
target
cv
life
cycl
focus
either
viral
protein
essenti
host
factor
compound
target
viral
protein
tend
less
side
effect
target
host
factor
decreas
likelihood
viru
develop
antivir
resist
amilorid
repurpos
antikaliuret
diuret
shown
abil
act
nonnucleosid
inhibitor
polymeras
pirlindol
initi
approv
antidepress
also
display
activ
protein
isol
plant
ornithogalum
saundersia
bind
host
oxysterolbind
protein
osbp
essenti
replic
mani
enterovirus
shown
inhibit
despit
advanc
specif
antivir
therapi
develop
cv
infect
treatment
remain
support
natur
role
vaccin
play
nearerad
polioviru
infect
signifi
effect
vaccin
may
invalu
combat
enteroviru
specif
cv
infect
recent
advanc
rhinoviru
vaccin
shown
broadrang
efficaci
primat
may
use
develop
vaccin
cv
figur
figur
origin
smallpox
uncertain
time
erad
variola
viru
anim
reservoir
depend
persist
entir
persontoperson
transmiss
run
clock
backward
suffici
number
human
larg
enough
group
maintain
viru
exist
bc
indic
must
jump
human
anim
host
time
earliest
physic
evid
smallpox
pustul
face
egyptian
mummi
around
rd
centuri
bc
frighten
natur
diseas
led
earli
effort
develop
mean
protect
variol
inocul
materi
smallpox
lesion
use
africa
asia
well
ad
practic
introduc
great
britain
ladi
mari
wortley
montagu
wife
ambassador
constantinopl
earli
midcenturi
becom
standard
practic
mani
part
europ
british
coloni
howev
procedur
traumat
produc
febril
ill
larg
cluster
pustul
inocul
site
small
percentag
variol
develop
fullblown
smallpox
british
countri
doctor
edward
jenner
without
understand
immun
awar
exist
virus
succeed
develop
new
safer
method
protect
smallpox
jenner
variol
boy
routin
perform
part
medic
practic
cours
work
rural
gloucestershir
notic
milkmaid
other
develop
cowpox
pustular
diseas
cattl
somehow
protect
smallpox
experiment
confirm
observ
scarifi
arm
yearold
boy
jame
phipp
materi
cowpox
lesion
hand
milkmaid
sarah
nelm
six
week
later
variol
boy
found
reaction
jenner
mental
leap
realiz
protect
variol
equat
protect
smallpox
earn
immort
histori
medicin
new
procedur
name
vaccin
latin
vacca
cow
rapidli
introduc
throughout
europ
new
world
led
declin
smallpox
diseas
persist
much
africa
asia
understand
infect
one
orthopoxviru
confer
crossimmun
member
genu
sometim
th
centuri
cowpox
viru
replac
vaccin
manufactur
viru
term
vaccinia
may
origin
horsepox
viru
whosponsor
erad
campaign
began
zero
last
remain
area
endem
smallpox
time
still
two
type
diseas
sever
form
variola
major
milder
form
variola
minor
last
person
world
contract
variola
major
threeyearold
girl
rahima
banu
live
bhola
island
bangladesh
becam
ill
isol
home
longer
infecti
happili
surviv
smallpox
erad
worker
initi
housetohous
vaccin
campaign
visit
everi
hous
public
meet
area
school
doctor
within
five
mile
ensur
ill
spread
ali
maow
maalin
somalia
last
person
develop
variola
minor
octob
close
contact
two
smallpox
patient
day
later
develop
fever
follow
rash
first
diagnos
malaria
chickenpox
smallpox
final
recogn
octob
isol
made
full
recoveri
ali
die
malaria
work
polio
erad
campaign
year
conclus
global
erad
campaign
offici
alarm
hear
outbreak
smallpox
england
janet
parker
medic
photograph
birmingham
univers
medic
school
work
one
floor
laboratori
henri
bedson
conduct
smallpox
research
came
fever
august
th
develop
rash
four
day
later
august
th
smallpox
final
diagnos
move
isol
hospit
die
two
week
later
total
person
contact
vaccin
place
surveil
mother
develop
smallpox
septemb
despit
vaccin
august
subsequ
investig
indic
janet
like
infect
via
airborn
rout
build
airduct
system
bedson
blame
escap
viru
commit
suicid
laboratori
close
event
led
call
worldwid
destruct
remain
stock
variola
viru
restrict
research
laboratori
follow
declar
global
erad
stockpil
smallpox
vaccin
greatli
reduc
effort
made
develop
safer
vaccin
person
impair
immun
attempt
made
identifi
antivir
drug
treatment
smallpox
vaccin
complic
variola
viru
store
use
whoapprov
research
center
diseas
control
prevent
atlanta
georgia
state
research
center
virolog
biotechnolog
vector
koltsovo
russia
elimin
natur
occur
smallpox
remov
threat
variola
viru
potenti
bioterrorist
weapon
inde
cessat
vaccin
render
current
world
popul
vulner
diseas
rapid
progress
biotechnolog
made
possibl
artifici
creat
variola
viru
similar
pathogen
laboratori
risk
accident
releas
variola
viru
one
two
whoapprov
research
laboratori
consid
neglig
instead
concern
focus
possibl
reemerg
smallpox
scientist
act
independ
employ
terrorist
organ
part
covert
statesponsor
biowarfar
effort
would
use
modern
molecular
method
reconstruct
viru
base
publish
sequenc
data
undeclar
secret
misplac
stock
variola
viru
might
also
exist
feasibl
creat
variola
viru
de
novo
demonstr
recent
construct
infecti
horsepox
viru
entir
chemic
synthes
dna
work
requir
sophist
knowledg
virolog
method
assembl
reaction
ineffici
necessari
infrastructur
wide
access
terrorist
might
instead
attempt
acquir
natur
occur
monkeypox
viru
zoonot
agent
maintain
variou
anim
speci
west
central
africa
monkeypox
viru
caus
smallpoxlik
diseas
human
although
much
milder
smallpox
viru
could
potenti
modifi
laboratori
increas
virul
insert
gene
encod
human
cytokin
interfer
protect
immun
respons
addit
possibl
use
bioterror
variola
viru
modifi
monkeypox
viru
could
weapon
introduct
gene
encod
peptid
protein
toxin
terrorist
arm
agent
might
releas
clandestin
aerosol
dens
popul
urban
center
transport
hub
infect
travel
might
carri
diseas
hundr
thousand
locat
worldwid
result
global
health
catastroph
scientif
progress
thu
paradox
increas
threat
return
smallpox
fortun
advanc
laboratori
also
lead
develop
safer
vaccin
new
antivir
drug
could
use
prevent
treat
diseas
medic
could
also
use
prevent
attenu
complic
tradit
vaccin
scientist
public
health
offici
recogn
threat
potenti
return
smallpox
decid
appropri
countermeasur
vaccin
use
global
erad
campaign
prepar
use
tradit
method
live
viru
harvest
lesion
skin
calv
firstgener
vaccin
prove
highli
efficaci
protect
differ
variola
viru
strain
well
relat
orthopoxvirus
longer
product
instead
replac
nd
rd
gener
vaccin
attempt
improv
manufactur
process
product
uniform
safeti
profil
tissueculturebas
nd
gener
vaccin
prepar
tissu
cultur
still
present
risk
advers
event
origin
vaccin
ie
unintent
transfer
live
vaccinia
viru
site
bodi
person
gener
vaccinia
eczema
vaccinatum
progress
vaccinia
myopericard
nd
gener
vaccin
store
larg
quantiti
us
strateg
nation
stockpil
recommend
young
children
month
age
peopl
exfoli
skin
diseas
individu
impair
immun
system
pregnant
breastfeed
women
patient
central
nervou
system
disord
heart
diseas
allerg
vaccin
compon
also
contraind
person
intim
household
contact
condit
due
risk
inadvert
infect
leav
consider
proport
human
popul
exclud
vaccin
thirdgener
smallpox
vaccin
base
replicationdefici
vaccinia
viru
strain
associ
advers
event
immun
reactiv
seem
lower
vaccin
could
given
individu
immun
defici
atop
dermat
work
continu
th
gener
dna
protein
vaccin
firstand
secondgener
smallpox
vaccin
highli
effect
administ
prophylact
howev
question
efficaci
administ
nonimmun
person
expos
variola
viru
yet
develop
sign
diseas
late
committe
overse
variola
viru
research
decid
protect
possibl
return
smallpox
would
requir
develop
effect
antivir
drug
addit
vaccin
similarli
us
institut
medicin
recommend
develop
least
two
oral
avail
therapeut
differ
mechan
action
time
vaccinia
immun
globulin
intraven
administr
vigiv
contain
high
titer
antivaccinia
neutral
antibodi
antipoxviru
therapeut
approv
fda
treatment
advers
event
smallpox
vaccin
current
tecovirimat
cidofovir
stockpil
usa
tecovirimat
develop
siga
inhibit
addit
second
outer
membran
develop
orthopoxviru
virion
prevent
exit
cell
oral
bioavail
neglig
toxic
tecovirimat
prove
efficaci
wide
rang
orthopoxvirus
vaccinia
cowpox
ectromelia
rabbitpox
monkeypox
variola
virus
laboratori
anim
compromis
develop
antibodi
combin
vaccin
prove
effect
postexposur
treatment
tecovirimat
receiv
first
global
approv
juli
treatment
smallpox
adult
children
weigh
kg
us
fda
anim
rule
market
approv
base
efficaci
relev
anim
model
stockpil
medic
cidofovir
would
much
less
use
set
smallpox
outbreak
requir
intraven
infus
coupl
supplement
hydrat
probenecid
prevent
nephrotox
overcom
drawback
intraven
drug
lipid
conjug
cidofovir
molecul
brincidofovir
develop
chimerix
synthes
prodrug
improv
oral
bioavail
increas
antivir
potenc
attribut
effici
cellular
uptak
facilit
lipid
moieti
brincidofovir
desir
characterist
emerg
consid
oral
bioavail
potent
antivariola
activ
need
short
cours
therapi
mechan
action
differ
tecovirimat
two
drug
prove
synergist
use
combin
addit
brincidofovir
larg
clinicalsafeti
databas
evid
nephrotox
hematolog
bone
marrow
toxic
consist
pk
data
healthi
infect
subject
brincidofovir
receiv
orphan
drug
design
focu
chimerix
get
antivir
accept
us
strateg
nation
stockpil
emerg
treatment
smallpox
antivir
drug
crucial
part
prepared
smallpox
outbreak
use
prophylaxi
prevent
diseas
nonvaccin
individu
popul
unabl
vaccin
postexposur
prophylaxi
treat
person
expos
variola
viru
yet
ill
therapi
individu
develop
smallpox
diseas
anoth
zoonot
poxviru
diseas
monkeypox
cowpox
combin
vaccin
prevent
smallpox
diseas
prevent
vaccin
complic
long
nd
gener
smallpox
vaccin
continu
use
two
antivir
differ
mode
action
need
treat
sever
case
vaccin
five
human
herpesvirus
known
ie
herp
simplex
viru
varicellazost
viru
vzv
human
cytomegaloviru
hcmv
epsteinbarr
viru
ebv
human
herpesviru
dharam
ablashi
robert
gallo
zaki
salahuddin
laboratori
tumor
cell
biolog
us
nation
cancer
institut
follow
discoveri
herpesviru
virolog
remain
spotlight
decad
first
isol
two
aid
patient
cancer
four
patient
lymphoprolif
disord
antigen
analysi
demonstr
six
isol
close
relat
sera
six
posit
patient
react
immunolog
viru
isol
found
morpholog
similar
differ
member
herpesviru
famili
though
uniqu
known
human
nonhuman
primat
herpesvirus
host
rang
vitro
biolog
featur
antigen
properti
origin
name
human
blymphotrop
viru
hblv
initi
found
bcell
infect
person
shown
effect
infect
freshli
isol
human
b
cell
induc
larg
refract
monoor
binucl
cell
nuclear
cytoplasm
inclus
bodi
howev
subsequ
research
reveal
cell
major
cell
type
infect
primari
infect
either
asymptomat
associ
roseola
koichi
yamanishi
group
discov
caus
agent
exanthema
subitum
roseola
infant
viru
isol
peripher
blood
lymphocyt
patient
exanthema
subitum
cultur
cord
blood
lymphocyt
prove
antigen
relat
human
morpholog
characterist
determin
thinsect
electron
microscopi
resembl
herpesvirus
convalescentphas
serum
sampl
test
antigen
seroconvers
shown
indic
newli
isol
viru
ident
close
relat
causal
agent
exanthema
subitum
earli
becam
clear
isol
recov
variou
geograph
region
clinic
set
could
stratifi
two
welldefin
group
differ
molecular
epidemiolog
biolog
properti
time
consensu
design
group
two
variant
speci
base
two
main
factor
interspeci
diverg
nucleic
acid
low
ii
partial
knowledg
differ
epidemiolog
pathogen
potenti
howev
base
subsequ
research
biolog
pathogen
mechan
virus
next
year
sever
author
began
suggest
two
variant
recogn
distinct
virus
herpesviru
subcommitte
intern
taxonomi
group
propos
two
variant
formal
recogn
distinct
virus
sever
epidemiolog
biolog
immunolog
differ
outlin
scientist
clinician
urg
differenti
two
virus
possibl
clariti
biolog
clinic
distinct
frenkel
colleagu
isol
new
human
herpesviru
cell
purifi
peripher
blood
mononuclear
cell
healthi
individu
rk
follow
incub
cell
condit
promot
tcell
activ
viru
could
recov
nonactiv
cell
rk
viru
prove
genet
relat
distinct
design
prototyp
new
herpesviru
seventh
human
herpesviru
anoth
isol
strain
ji
recov
patient
socal
chronic
fatigu
syndrom
subsequ
isol
saliva
signific
number
healthi
adult
select
tropism
lymphocyt
glycoprotein
essenti
element
cellular
membran
receptor
last
known
human
herpesviru
ie
discov
mean
molecular
techniqu
kaposi
sarcoma
ks
lesion
bcell
lymphoma
abdomin
caviti
sequenc
kaposi
sarcoma
associ
herpesviru
kshv
found
homolog
distinct
capsid
tegument
protein
gene
ebv
prototyp
genu
lymphocryptoviru
herpesviru
saimiri
prototyp
rhadinoviru
genu
found
strongli
associ
kaposi
sarcoma
multicentr
castleman
diseas
primari
effus
lymphoma
classifi
member
subfamili
member
roseoloviru
genu
subfamili
genet
relat
hcmv
type
speci
human
amino
acid
ident
approxim
wide
distribut
human
popul
primari
infect
occur
usual
month
year
later
preval
gener
popul
precis
determin
although
infect
caus
asymptomat
though
primari
infect
sometim
associ
exantema
subitum
rosela
infantum
sixth
diseas
case
primari
infect
may
link
sever
condit
meningoenceph
respiratori
digest
syndrom
macrophag
activ
syndrom
symptomat
primari
infect
less
welldocu
compar
caus
clear
primari
infect
poorli
document
except
potenti
case
exanthema
subitum
also
caus
opportunist
infect
patient
impair
immun
instanc
common
present
includ
enceph
neurocognit
impair
delay
engraft
hematopoiet
stem
transplant
recipi
summar
tabl
diseas
associ
infect
depend
statu
viral
infect
replic
effici
human
cord
blood
mononuclear
cell
peripher
blood
mononuclear
cell
well
variou
tcell
line
virus
also
establish
latenc
cell
line
recent
work
benedikt
kaufer
lab
demonstr
cellular
nuclear
domain
complex
part
intrins
antivir
respons
play
import
role
suppress
lytic
replic
silenc
viru
genom
latent
infect
cell
share
hcmv
sever
gene
encod
product
involv
viral
replic
serv
target
antivir
therefor
mani
drug
activ
hcmv
show
activ
vitro
includ
ganciclovir
foscarnet
cidofovir
contrast
acyclovir
use
treat
effect
vitro
mark
prichard
team
univers
alabama
develop
new
method
assess
antivir
activ
dna
virus
use
autom
format
qpcr
measur
viral
dna
accumul
among
fda
approv
drug
foscarnet
display
highest
select
index
pipelin
drug
filociclovir
cyclopropavir
brincidofovir
show
promis
rel
low
effect
concentr
howev
unknown
well
drug
abl
pass
bloodbrain
barrier
valganciclvoir
oral
prodrug
form
ganciclovir
efficaci
reactiv
bone
marrow
transplant
patient
efficaci
hcmv
hcmv
gcv
escap
mutant
report
transplant
recipi
ganciclovirresist
virus
alter
protein
kinas
homolog
hcmv
protein
kinas
requir
phosphoryl
gcv
well
dna
polymeras
antivir
agent
offici
approv
treatment
consensu
initi
antivir
treatment
studi
antivir
treatment
limit
clinic
case
patient
need
develop
conduct
welldesign
studi
valid
treatment
infect
caus
uniqu
featur
abil
integr
human
chromosom
form
latenc
occur
approxim
gener
worldwid
popul
viru
integr
germlin
cell
offspr
born
full
copi
genom
everi
nucleat
cell
uniqu
among
human
herpesvirus
sinc
specif
effici
integr
telomer
chromosom
latenc
rather
form
episom
telomer
repeat
ident
human
telomer
sequenc
locat
end
viral
genom
dispens
viru
replic
crucial
integr
mainten
viru
genom
latent
infect
cell
chromosom
integr
origin
consid
dead
end
form
latenc
integr
known
capabl
produc
virion
mother
carri
demonstr
infect
children
placenta
also
group
led
peter
medveczki
univers
south
florida
demonstr
viru
activ
stimul
integr
cell
chemic
conveni
method
determin
patient
perform
whole
blood
quantit
pcr
dna
test
viral
load
copi
per
ml
absenc
acut
ill
attribut
viral
load
individu
occasion
copi
per
ml
whole
blood
case
extrem
ill
enceph
acut
episod
graftversushost
diseas
extrem
drug
hypersensit
suspicion
confirm
test
patient
parent
least
one
two
would
high
posit
result
test
fish
analysi
confirm
pcr
also
done
fingernail
hair
follicl
individu
posit
person
would
posit
pcr
test
fingernail
hair
follicl
da
munoz
propos
determin
statu
donorsrecipi
organ
transplant
use
singl
pretranspl
qpcr
test
whole
blood
care
monitor
patient
organ
sign
activ
infect
evalu
plasma
pcr
use
assess
viral
reactiv
individu
due
high
background
level
dna
lyse
cell
assay
measur
viral
mrna
reveal
whether
viru
replic
exanthema
subitum
roseola
infantum
sixth
diseas
confirm
fever
seizur
mild
respiratori
digest
symptom
thrombocytopenia
virallik
syndrom
mononuclear
cell
blood
enceph
hepat
coliti
macrophag
activ
syndrom
tempor
lobe
epilepsi
fever
skin
rash
thrombocytopenia
leukopenia
anemia
myelosuppress
enceph
neurocognit
deficit
hepat
coliti
gastroenter
retin
pneumon
druginduc
hypersensit
syndrom
dress
tempor
lobe
epilepsi
graftversushost
diseas
gvhd
thrombot
microangiopathi
chronic
infect
multipl
sclerosi
hashimoto
thyroid
myocard
chronic
cardiomyopathi
rapid
progress
toward
aid
infect
hivposit
patient
alzheim
diseas
chromosom
integr
increas
risk
angina
pectori
suggest
associ
confirm
adapt
suddenli
lot
interest
scientif
commun
along
appear
central
progress
alzheim
diseas
ad
two
recent
paper
neuron
provid
new
evid
link
herpesvirus
ad
use
transgen
ad
mice
express
human
human
neural
cell
cultur
eimer
colleagu
demonstr
infect
dramat
acceler
deposit
peptid
oligom
shown
bind
herpesviru
surfac
glycoprotein
acceler
deposit
lead
protect
viral
entrap
activ
mous
human
neural
cell
cultur
infect
model
protect
viral
entrap
reactiv
pathogen
prevent
virus
infect
brain
cell
howev
protect
effect
lead
format
fibril
plaqu
patholog
hallmark
alzheim
diseas
team
led
joel
dudley
base
mount
sinai
new
york
inspect
ad
brain
sampl
known
human
virus
notic
discov
ad
brain
transcript
increas
although
also
evid
overrepresent
transcript
research
also
found
higher
level
dna
point
activ
viral
replic
ad
brain
moreov
presenc
prove
significantli
associ
sever
dementia
brain
patholog
note
similarli
wellknown
caus
viral
enceph
particular
immunocompromis
individu
also
link
demyelin
brain
diseas
studi
brought
herpesvirus
front
crucial
contributor
develop
ad
increas
hope
interest
search
novel
antivir
herpesvirus
ben
berkhout
laboratori
experiment
virolog
amsterdam
umc
univers
amsterdam
netherland
bberkhout
amcuvanl
rna
interfer
rnai
mechan
gene
suppress
discov
nematod
caenorhabd
elegan
upon
introduct
short
doublestrand
rna
segment
rna
molecul
process
cell
trigger
degrad
translat
inactiv
mrna
complementari
nucleotid
sequenc
discoveri
rnamedi
regul
gene
express
posttranscript
level
discover
andrew
fire
craig
mello
nobel
prize
physiolog
key
compon
rnai
mechan
wellconserv
among
differ
kingdom
plant
anim
mammal
rnai
mechan
constitut
addit
level
regul
gene
express
perform
larg
set
regulatori
small
doublestrand
microrna
mirna
mirna
matur
help
cellular
endonucleas
drosha
dicer
subsequ
interact
argonaut
protein
key
mrnaslic
compon
rnainduc
silenc
complex
risc
among
thing
rnai
shown
act
innat
mechan
suppress
activ
transposon
jump
gene
link
induct
diseas
like
duchenn
muscular
dystrophi
human
rnai
also
propos
antivir
mechan
initi
plant
later
mammal
although
latter
claim
remain
disput
time
relev
rnai
concept
field
virolog
actual
obviou
start
sometim
nobel
prize
discoveri
earli
find
plant
viru
field
alreadi
hint
novel
rnabas
mechan
call
rna
silenc
control
gene
express
posttranscript
level
key
find
accumul
characterist
short
interf
rna
sirna
virusinfect
plant
rna
silenc
use
cellular
rnai
compon
function
play
import
role
mediat
cellular
defenc
infect
plant
virus
plant
defect
rna
silencingrnai
suscept
infect
viral
pathogen
plant
virus
turn
evolv
potent
antirnai
mechan
express
protein
transcript
rnaisuppressor
activ
import
conserv
rnai
antivir
respons
underscor
observ
transkingdom
suppress
human
viral
protein
plant
vice
versa
rnai
also
major
antivir
mechan
insect
like
drosophila
melanogast
remain
uncertain
quit
time
execut
similar
function
higher
eukaryot
said
complet
machineri
present
mammalian
cell
execut
critic
mirna
program
furthermor
also
know
rnai
induc
synthet
sirna
viral
pathogen
prove
rnai
mechan
execut
essenti
antivir
program
real
life
one
reason
immedi
accept
scenario
mammal
alreadi
two
robust
antivir
defens
system
innat
interferon
adapt
immun
system
anoth
reason
absenc
typic
sirna
signatur
earli
studi
virusinfect
cell
tide
recent
turn
favor
rnaimedi
antivir
immun
mammal
first
studi
virusinfect
embryon
stem
cell
lack
function
interferon
system
reveal
characterist
virusspecif
sirna
signatur
decreas
abund
upon
differenti
cell
second
viral
sirna
signatur
also
appar
cell
infect
mutant
viru
encod
rnai
suppressor
protein
third
mutant
viru
lack
rnai
suppressor
protein
replic
rescu
rnaidefici
cell
thu
cellular
rnai
program
could
link
potent
antivir
respons
unimportantli
studi
also
provid
reason
mammalian
antivir
rnai
remain
obscur
long
virul
viru
strain
encod
potent
rnai
suppressor
mask
sirna
signatur
higher
sirna
level
score
undifferenti
pluripot
cell
express
less
interferon
mask
effect
confirm
recent
studi
human
enteroviru
compar
wildtyp
viru
mutant
lack
suppressor
protein
mutant
show
sever
replic
defici
could
overcom
dicerdefici
exclud
interferon
effect
qiu
et
al
use
mous
cell
lack
function
interferon
receptor
drug
specif
block
pathway
thu
mammal
seem
develop
least
three
antivir
mechan
rnai
undifferenti
cell
top
innat
adapt
immun
system
recent
evid
indic
invertebr
also
evolv
multipl
antivir
pathway
yet
plant
seem
reli
exclus
rnai
mechan
rnai
develop
power
research
tool
allow
scientist
suppress
express
specif
gene
synthet
doublestrand
rna
recent
crisprca
method
surpass
rnai
techniqu
especi
true
knockout
phenotyp
requir
rnai
also
develop
new
therapi
approach
varieti
diseas
includ
viral
infect
rna
virus
transcript
dna
virus
target
one
could
also
consid
inhibit
critic
cellular
cofactor
one
could
address
acut
persist
infect
eg
caus
respiratori
syncyti
viru
human
immunodefici
viru
attack
sequencespecif
one
expect
viral
escap
occur
select
singl
point
mutat
inde
observ
prolong
hiv
cultur
experi
similar
clinic
success
current
antihiv
regimen
consist
multipl
drug
combinatori
rnai
approach
may
develop
prevent
viral
escap
uncommon
clinic
translat
rnai
knowledg
turn
rocki
path
unexpect
side
effect
requir
shield
therapeut
rna
degrad
achiev
target
right
organ
cellular
uptak
recent
first
drug
onpattro
produc
alnylam
approv
treat
hereditari
form
nerv
degener
still
await
first
antivir
rnai
drug
intervent
control
aed
aegypti
latin
america
caribbean
systemat
review
qualit
studi
indepth
interview
expert
polici
dialog
decisionmak
object
experi
systemat
review
intervent
use
latinamerica
worldwid
identifi
experi
barrier
facilit
implement
intervent
control
aa
latin
america
caribbean
la
c
seek
expert
opinion
regard
action
need
prevent
control
infect
zika
dengu
chikungunya
delib
polici
dialogu
decis
maker
could
discuss
matter
three
manuscript
gener
polici
dialogu
report
accept
public
caderno
de
systemat
review
current
peer
review
plo
neglect
tropic
diseas
qualit
studi
also
peer
review
former
journal
systemat
review
sr
summar
inform
identifi
la
c
region
regard
intervent
vector
control
year
conduct
comprehens
literatur
review
main
databas
assess
methodolog
qualiti
studi
includ
inform
came
brazil
argentina
cuba
mexico
peru
random
control
trial
identifi
moder
low
methodolog
qualiti
region
found
sever
intervent
show
effect
vari
degre
insecticidetr
materi
may
reduc
entomolog
indic
experiment
quasiexperiment
studi
although
mani
trial
reach
statist
signific
evid
also
indic
health
educ
commun
engag
assess
knowledg
preventionrel
attitud
proven
effect
intervent
intervent
also
proven
use
systemat
review
search
literatur
databas
like
medlin
embas
central
socindex
lilac
januari
septemb
includ
experiment
quasiexperiment
observ
studi
econom
assess
qualit
studi
assess
incid
morbiditymort
aarel
diseas
follow
entomolog
indic
breteau
contain
hous
pupa
per
person
use
grade
methodolog
assess
qualiti
evid
total
number
completetext
assess
studi
includ
cluster
random
clinic
trial
includ
metaanalysi
identifi
intervent
support
high
certainti
evid
health
educ
commun
engag
may
probabl
reduc
entomolog
indic
well
insecticidetr
materi
likewis
use
indoor
residu
spray
manag
contain
may
also
improv
although
confid
interv
includ
reduct
increas
indic
found
low
certainti
evid
support
use
ovitrap
larvitrap
integr
epidemiolog
surveil
improv
entomolog
indic
decreas
incid
dengu
degre
implement
intervent
variabl
differ
countri
set
found
although
mani
intervent
carri
region
hand
provid
scientif
sound
evid
effect
extend
whole
citi
sustain
beyond
two
year
remain
import
engag
educ
commun
work
author
achiev
implement
integr
action
health
sector
sector
nation
region
level
second
manuscript
part
endeavor
entitl
experi
barrier
facilit
implement
aa
control
intervent
latin
america
caribbean
qualit
studi
studi
use
induct
inquiri
consist
ground
theori
approach
includ
indepth
semistructur
interview
stakehold
countri
argentina
brazil
colombia
cuba
hondura
paraguay
peru
puerto
rico
data
collect
perform
juli
juli
undertook
themat
analysi
develop
matric
facilit
comparison
across
transcript
materi
retain
context
data
final
abstract
interpret
data
interviewe
point
view
initi
control
infect
transmit
mosquito
usual
start
reaction
outbreak
intervent
mainli
orient
elimin
adult
mosquito
form
barrier
success
implement
intervent
classifi
six
level
biophys
health
system
factor
health
govern
commun
public
opinion
regard
biophys
condit
climat
condit
natur
built
environ
barrier
underlin
unpredict
occurr
outbreak
due
climat
chang
main
barrier
identifi
within
health
system
lack
materi
resourc
capabl
personnel
public
health
prioriti
hardli
ever
includ
vector
control
program
discontinu
lack
prevent
initi
lack
budget
alloc
factor
differ
health
great
impact
prevent
deal
garbag
collect
educ
built
environ
tradit
priorit
public
health
problem
also
may
lack
resourc
govern
level
barrier
relat
discontinu
program
lack
budget
alloc
absenc
effect
function
link
polit
decis
expert
recommend
lack
programmat
coordin
local
govern
commun
level
lack
inform
educ
conspir
risk
percept
awar
moreov
perceiv
reluct
implement
prevent
action
regard
public
opinion
identifi
media
messag
may
oper
public
polici
need
strengthen
implement
continu
vector
control
program
latin
america
studi
contribut
identifi
main
barrier
may
inform
prioriti
action
order
improv
prevent
vectorborn
diseas
lastli
undertook
polici
dialogu
describ
manuscript
workshop
priorit
intervent
control
aa
mosquito
la
c
polici
dialogu
narrat
experi
carri
workshop
decis
maker
expert
la
c
priorit
intervent
research
control
aa
mosquito
delib
process
done
collect
instanc
assist
result
aforement
project
consensu
list
prioriti
implement
vector
control
strategi
region
develop
key
research
line
develop
agre
best
strategi
integr
vector
manag
integr
manag
strategi
disaggreg
chemic
control
b
biolog
control
c
environment
manag
commun
particip
e
integr
surveil
fundament
nontransferr
stewardship
role
state
intersector
coordin
state
agenc
civil
societi
actor
highlight
propos
priorit
follow
research
line
analyz
vector
capac
aa
associ
factor
assess
commun
compon
intervent
incorpor
technolog
vector
control
monitor
effici
mode
integr
surveil
entomolog
indic
better
predict
capac
resist
insecticid
methodolog
polici
dialogu
allow
us
dissemin
valid
enrich
result
previou
instanc
research
within
framework
conven
work
dynam
guid
futur
line
would
allow
offer
consist
evid
vector
control
aa
la
c
thu
rais
dialogu
decis
maker
expert
translat
two
main
prioriti
region
strategi
vector
control
research
agenda
allow
pool
effort
enhanc
capac
orient
resourc
toward
intervent
research
prioriti
particip
well
repres
pan
american
health
organ
paho
welcom
initi
undertook
follow
propos
emerg
well
possibl
establish
network
collabor
activ
commun
facilit
object
zika
viru
zikv
first
isol
uganda
circul
human
popul
west
africa
asia
sinc
littl
attent
devot
zikv
probabl
due
mild
symptom
fact
geograph
restrict
neglect
diseas
histori
howev
start
chang
land
zikv
french
polynesia
associ
increas
rate
guillainbarr
syndrom
autoimmun
condit
affect
peripher
nervou
system
trigger
infect
two
year
polynesian
outbreak
unpreced
epidem
regist
brazil
zikv
becam
extraordinari
health
burden
due
novel
correl
infect
pregnant
women
sever
brain
malform
newborn
brazil
regist
averag
case
microcephali
per
year
end
number
risen
pernambuco
first
state
report
unusu
number
microcephali
case
newborn
time
report
averag
entir
countri
previou
five
year
number
report
case
continu
increas
regist
novemb
end
locat
northeast
state
highest
number
microcephali
case
relat
zikv
infect
nine
northeast
evid
causal
link
zikv
microcephali
formal
accept
april
mechan
zikv
cross
placenta
still
unclear
neurotrop
abil
destroy
neural
cell
clearli
demonstr
zikv
infect
induc
abnorm
mitosi
apoptosi
human
neural
progenitor
cell
npc
caus
disrupt
lesion
fetal
central
nervou
system
cn
npc
primari
target
zikv
may
partli
explain
high
number
abnorm
seen
cn
detect
neuroimag
examin
howev
microcephali
one
mani
zikvrel
birth
complic
refer
congenit
zika
syndrom
cz
children
born
cz
normal
head
size
children
born
without
abnorm
later
found
develop
brain
damag
development
problem
evid
accumul
subtl
destruct
brain
ear
ocular
injuri
also
occur
infant
normal
head
size
birth
expand
rang
anomali
may
difficult
imposs
diagnos
prenat
remain
uncertainti
longterm
neurocognit
effect
zikv
exposur
addit
zikv
infect
trimest
pregnanc
may
result
cz
even
asymptomat
present
zikv
consid
new
member
teratogen
congenit
infect
zikv
outbreak
brazil
trigger
larg
mobil
technic
scientif
apparatu
societi
media
mandatori
notif
zikv
commenc
februari
howev
report
zikv
case
confirm
misdiagnos
dengu
zikv
chikungunya
might
occur
earli
epidem
addit
accur
laboratori
diagnosi
challeng
due
short
viremia
period
crossreact
among
dengu
zikv
serodiagnost
unpreced
natur
diseas
rais
doubt
expect
popul
fear
anxieti
becam
part
daili
live
pregnant
women
famili
especi
brazil
south
american
countri
affect
despit
notabl
increas
scientif
focu
path
cz
leav
puzzl
question
unansw
phylogenet
point
view
two
main
lineag
zikv
african
asian
lineag
estim
asian
lineag
enter
america
sinc
zikv
genom
experienc
sever
mutat
function
implic
genom
chang
activ
topic
studi
rapid
geograph
dispers
attribut
ubiquit
presenc
vector
mosquito
genu
aed
moreov
find
zikv
also
sexual
transmit
expand
transmiss
channel
also
broaden
geograph
reach
tropic
countri
end
zikv
infect
report
approxim
countri
across
main
contin
total
countri
report
case
microcephali
congenit
anomali
potenti
caus
zikv
infect
notabl
cz
case
report
brazil
northeast
region
brazil
link
zikv
microcephali
spur
govern
leader
latin
america
suggest
women
postpon
babi
year
ignor
fact
region
onehalf
pregnanc
intend
rate
sexual
violenc
high
abort
legal
restrict
women
seek
clandestin
abort
selfinduc
termin
pregnanc
mostli
unsaf
condit
brazil
abort
allow
save
woman
life
case
rape
absenc
treatment
prevent
zikv
cross
placenta
legal
abort
polici
women
legal
framework
exercis
choic
continu
termin
pregnanc
follow
zikv
infect
present
ultrasound
show
problem
fetal
develop
would
carri
pregnanc
face
risk
deliv
child
congenit
problem
put
health
risk
induc
abort
although
zikv
outbreak
regist
similar
proport
across
mani
geograph
area
inform
case
cz
cluster
indic
asymmetr
distribut
among
human
popul
peculiar
open
sever
question
symptom
distribut
wide
spread
viru
vari
significantli
region
appar
also
time
specif
factor
preval
northeast
region
among
certain
popul
increas
sever
zikv
pregnanc
signific
cofactor
popul
help
determin
observ
pattern
current
evid
factor
exist
global
biomed
research
reaction
understand
cz
remark
coordin
effort
necess
strengthen
support
epidemiolog
surveil
help
direct
prevent
also
provid
inform
scientif
valu
futur
becam
evid
zikv
infect
number
drop
dramat
cz
patient
born
almost
inexist
south
america
plausibl
explan
pattern
may
immun
vast
major
atrisk
popul
howev
specif
serolog
analys
remain
necessari
confirm
addit
genet
background
environment
context
factor
affect
immun
statu
respons
zikv
infect
human
popul
environment
factor
impact
immun
statu
strongli
relat
socioeconom
posit
hous
condit
malnutrit
coinfect
suscept
amongst
variabl
differ
region
well
popul
may
contribut
differ
respons
zikv
infect
analyz
relationship
recif
pernambuco
citi
sever
affect
found
case
report
microcephali
larg
concentr
area
impoverish
live
condit
commun
lower
socioeconom
statu
degrad
hous
facilit
zikv
transmiss
enhanc
mosquito
reproduct
human
access
fact
dengu
viru
preval
area
brazil
found
strongli
relat
live
condit
although
ecolog
vectorbas
hypothesi
provid
fertil
area
studi
could
describ
potenti
increas
infect
case
may
fall
short
explain
geograph
region
character
similar
level
zikv
infect
pregnanc
impact
differ
cz
two
hypothes
associ
cz
epidem
use
larvicid
pyriproxyfen
vaccin
administr
pregnanc
dismiss
recent
casecontrol
studi
recif
coinfect
flavivirus
transmit
vector
aed
mosquito
could
play
role
immun
respons
zikv
infect
dengu
viru
exampl
endem
south
america
seropreval
found
popul
within
csz
cluster
region
known
initi
infect
dengu
viru
posterior
exposur
dengu
serotyp
could
result
lifethreaten
complic
due
phenomenon
known
antibodydepend
enhanc
antibodi
protect
infect
serotyp
infect
one
three
serotyp
antibodydepend
enhanc
phenomenon
describ
process
antibodi
gener
first
infect
bind
new
viru
fail
effici
neutral
instead
phenomenon
facilit
viru
entri
target
cell
sinc
zikv
structur
close
dengu
viru
sever
studi
examin
crossreact
studi
demonstr
antibodi
gener
initi
dengu
infect
bind
high
level
affin
zikv
significantli
enhanc
pathogenesi
ultim
fail
counteract
viru
mechan
viral
enhanc
thought
mediat
immunoglobulin
g
engag
fc
gamma
receptor
agreement
antibodydepend
enhanc
exampl
nutrit
addit
cofactor
tie
socioeconom
demograph
condit
posit
correl
incom
well
develop
level
demonstr
interfer
immun
malnutrit
due
insuffici
intak
nutrient
lead
impair
immun
function
sever
innat
adapt
pathway
studi
may
explor
link
specif
cofactor
case
birth
defect
produc
zikv
infect
date
drug
approv
treatment
zikv
flaviviru
infect
treatment
zikv
infect
primarili
consist
support
measur
rest
zikv
usual
selflimit
infect
howev
persist
infect
male
reproduct
tract
sexual
transmiss
abil
cross
placenta
pregnanc
infect
develop
fetu
caus
congenit
malform
associ
syndrom
adult
unusu
clinic
featur
zikv
although
incid
zikv
case
declin
threat
gone
ae
aegypti
reign
brazilian
citi
current
transmit
dengu
zika
chikungunya
mayaro
viru
compet
transmit
strain
yellow
fever
viru
circul
countri
inde
urban
yellow
fever
record
brazil
year
urban
transmiss
success
elimin
new
epidem
zikv
possibl
could
exacerb
climat
condit
conclus
zikv
provid
exampl
import
constant
dialogu
experiment
epidemiolog
viral
vigil
work
zikv
emerg
medic
concern
end
answer
mani
question
came
collabor
work
look
recent
develop
antivir
nucleotid
highli
innov
success
drug
candid
keep
pop
believ
far
exploit
chemic
space
class
compound
also
focu
research
set
background
carbohydr
chemistri
provid
perfect
basi
sinc
import
straightforward
techniqu
synthes
nucleosid
use
method
carbohydr
chemistri
moreov
studi
phosphoryl
carbohydr
synthesi
move
nucleotid
chemistri
alreadi
experi
phosphoryl
reaction
product
isol
often
challeng
postdoc
meier
lab
opportun
learn
excel
expert
nucleotid
chemistri
combin
curiositydriven
research
latest
innov
prodrug
technolog
enabl
confid
success
take
challeng
project
cours
hold
true
join
virolog
chemotherapi
lab
rega
institut
train
virolog
expert
prestigi
institut
understand
biolog
side
antivir
research
hope
combin
best
world
research
answer
question
current
project
aim
contribut
understand
intracellular
activ
process
antivir
pseudobas
recent
identifi
novel
intracellular
nucleotidemetabolit
defluorofavipiravir
also
present
porto
want
understand
relev
hope
gain
insight
relationship
chemic
structur
mode
action
antivir
pseudobas
nucleosid
analogu
research
combin
experi
chemic
synthesi
phosphoryl
biomolecul
gain
chri
meier
lab
hamburg
skill
develop
stay
liev
naesen
group
leuven
first
research
stay
rega
institut
award
chu
famili
foundat
scholarship
roundtabl
pari
turn
extrem
valuabl
reward
experi
work
interfac
two
disciplin
want
abl
speak
languag
chemistri
languag
biolog
abl
follow
detail
antivir
studi
better
understand
interpret
result
limit
experi
also
believ
open
effici
commun
basi
product
enjoy
collabor
sinc
passion
nucleotid
chemistri
antivir
drug
discoveri
choic
want
learn
biolog
virolog
approach
easi
rega
institut
prestigi
past
lead
discoveri
promin
antihiv
drug
vibrant
present
mani
import
contribut
ie
discoveri
druglead
treatment
newli
emerg
viral
pathogen
make
place
excel
research
institut
got
chanc
work
inspir
scientist
learn
expert
field
way
could
also
expand
network
antivir
research
beyond
rega
institut
sinc
lab
foster
mani
intern
collabor
moreov
leuven
love
town
got
chanc
stay
groot
begijnhof
picturesqu
place
date
centuri
list
unesco
world
heritag
never
experienc
special
atmospher
place
creat
perfectli
mix
pioneer
research
stateoftheart
facil
ku
leuven
rega
institut
first
threemonth
stay
award
anoth
scholarship
followup
project
month
liev
group
collabor
project
success
yield
public
j
med
chem
chanc
present
result
icar
atlanta
porto
support
travel
award
isar
phd
attend
two
big
carbohydr
chemistri
confer
love
inspir
atmospher
meet
opportun
get
direct
feedback
regard
research
start
postdoc
project
attend
icar
meet
first
time
rome
impress
scienc
present
met
liev
naesen
mani
research
rega
institut
first
time
start
close
collabor
antiinfluenza
viru
nucleotid
consequ
gave
opportun
get
fund
go
abroad
isar
opportun
get
know
peopl
support
career
extrem
grate
encourag
mentorship
isar
enabl
join
icar
meet
gener
support
travel
award
grate
network
isar
creat
connect
topnotch
intern
lab
open
new
member
young
research
foster
posit
support
inspir
atmospher
futur
hope
contribut
scienc
also
introduc
new
member
young
research
societi
teach
mentor
student
extrem
reward
part
scientist
student
take
first
step
research
bring
lot
enthusiasm
curios
drive
research
creat
atmospher
want
foster
lab
yet
research
pose
big
challeng
initi
approach
answer
scientif
question
rare
work
one
start
frustrat
big
part
daili
busi
one
need
enorm
dilig
persist
selfmotiv
research
believ
open
commun
mentor
experienc
lab
partner
well
part
team
help
overcom
challeng
talk
advisor
fellow
student
identifi
accomplish
especi
nt
present
first
sight
celebr
togeth
regret
mainli
relat
person
life
interperson
relationship
good
way
rememb
everyon
make
mistak
must
strength
face
consequ
person
look
far
futur
never
speak
work
allow
free
calm
make
decis
expect
come
year
teach
class
univers
work
hard
subject
realli
like
went
first
summer
school
ph
student
first
year
found
extrem
use
excit
time
fourth
meet
organ
committe
mainli
look
logist
correspond
student
nice
contact
email
send
look
alreadi
enthusiast
particip
look
forward
school
start
good
scienc
also
lot
fun
meant
sinc
first
summer
school
perfect
mix
lectur
emin
scientist
morn
poster
oral
present
student
afternoon
mix
background
disciplin
involv
antivir
develop
highli
interact
environ
everi
moment
breakfast
dinner
share
student
teacher
everi
student
opportun
learn
present
hisher
project
get
suggest
importantli
confront
himselfherself
student
face
difficulti
ph
impli
environ
may
encourag
ask
advic
experienc
scientist
around
readi
answer
make
awar
futur
possibl
opportun
distinguish
choos
supervis
student
excit
challeng
frustrat
spring
enthusiasm
get
fascin
research
devot
learn
grow
also
bore
careless
matter
hard
tri
involv
experi
hand
give
great
satisfact
mmmm
phd
like
marathon
mental
physic
tri
get
tire
earli
get
passion
project
tri
phagocyt
sport
save
time
friend
take
occas
meet
new
peopl
learn
alway
behind
someth
alway
late
alway
dwell
thing
lucki
enough
side
person
love
support
lot
friend
know
enough
well
face
hyper
organ
tempera
humor
point
let
profession
life
overcom
person
one
tri
balanc
two
may
say
research
inde
difficult
hard
switch
brain
work
project
excit
worri
arriv
home
slowli
learn
must
say
think
isar
great
societi
friendli
especi
young
scientist
sinc
begin
tri
involv
help
characterist
aspect
particularli
like
first
high
level
interdisciplinari
link
among
member
someth
pharmaceut
chemist
made
feel
home
sinc
first
meet
attend
raleigh
four
year
ago
meet
high
level
scienc
everi
time
come
home
mani
new
idea
sometim
even
complet
new
project
start
lab
colleagu
make
fun
time
meet
becom
even
nicer
know
peopl
rememb
year
year
also
possibl
big
meet
nice
network
incub
think
societi
offer
mani
opportun
young
scientist
women
particular
support
mani
time
attend
meet
isar
thank
women
scienc
program
also
research
abroad
help
lot
improv
skill
could
use
back
home
worthwhil
fantast
experi
isar
news
offici
public
intern
societi
antivir
research
publish
four
time
year
free
articl
antivir
research
http
wwwjournalselseviercomantiviralresearch
post
isar
websit
http
wwwisaricarcom
except
state
otherwis
photograph
publish
permiss
isar
